Lungs and Genetic Testing
Lungs and Genetic Testing

Non-Small Cell Lung Cancer (NSCLC) and KRAS G12C: Fast Facts

KRAS G12C in NSCLC is now an actionable biomarker. Here are eight fast facts you should know.

 

 

  1. Lung cancer is by far the leading cause of cancer death among both men and women, making up more than 25% of cancer deaths.1
     
  2. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases.1
     
  3. Despite recent advances in the treatment of advanced lung cancer, there remains a high unmet need for patients and outcomes remain poor.2
     
  4. 50% of NSCLC patients have an oncogene, that initiates cancer and contributes to its growth.3
     
  5. KRAS G12C, a newly actionable biomarker, occurs in 13%, or 1 in 8 NSCLC patients in the U.S.4
     
  6. Comprehensive biomarker testing at diagnosis is critical because it can help patients develop a targeted and personalized treatment plan.5,6
     
  7. Depending on stage at diagnosis and a patient’s biomarker status, NSCLC treatment options may include chemotherapy, immunotherapy, radiation, surgery, or targeted therapies.7
     
  8. For patients with a mutational driver identified by biomarker testing, treatment with targeted therapy is associated with improved outcomes for patients.6*
     
KRAS  NSCLC Fact Sheet

 

  1. ACS. About Lung Cancer – Key Statistics. Available at: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed 4/25/2021.
  2. ACS. Early Detection, Diagnosis, and Staging – Lung Cancer Survival Rates. Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed 4/25/2021.
  3. Baumgart M. Am J Hematol Oncol. 2015;11:10-13.
  4. Amgen Data on File: Analysis of AACR Genie v8, 7-A-Table.
  5. Barlesi F, et al. Lancet. 2016;387:1415-1426.
  6. Kris MG, et al. JAMA. 2014;311: 1998-2006.
    6* Median overall survival (mOS) of 3.5 months in patients receiving targeted therapy enabled by biomarker testing compared to 2.4 months mOS in patients with a driver mutation not receiving targeted therapy.
  7. ACS. Treating Non-Small Cell Lung Cancer. Available at: https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell.html. Accessed 4/25/21.

     

 

Tags

Share This Story